We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$580M
AUM Growth
-$29.5M
Cap. Flow
-$5.55M
Cap. Flow %
-0.96%
Top 10 Hldgs %
70.73%
Holding
51
New
5
Increased
16
Reduced
15
Closed
15
Avg Time Held
4.9 quarters
Top 10 Avg Time Held
3.6 quarters
Top 20 Avg Time Held
4.1 quarters

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$45.5M
2
BSX icon
Boston Scientific
BSX
+$25.8M
3
IRTC icon
iRhythm Holdings
IRTC
+$18.1M
4
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$14M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$12.3M

Top Sells

Rank Stock Value
1
PRCT icon
Procept Biorobotics
PRCT
+$42M
2
MGTX icon
MeiraGTx Holdings
MGTX
+$25.2M
3
WGS icon
GeneDx Holdings
WGS
+$24.9M
4
KURA icon
Kura Oncology
KURA
+$12.6M
5
CON icon
Concentra Group Holdings
CON
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.79%
2 Technology 0.21%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PFE icon
26
Pfizer
PFE
$162B
$3.26M 0.56%
+135,366
New +$3.54M
2026 Q2
0 quarters
KIDS icon
27
OrthoPediatrics
KIDS
$573M
$3.01M 0.52%
157,500
-144,899
-48% -$2.52M
2025 Q2
4 quarters
RCKT icon
28
Rocket Pharmaceuticals
RCKT
$252M
$2.39M 0.41%
700,000
+16,144
+2% +$53.7K
2024 Q3
7 quarters
ANTX icon
29
AN2 Therapeutics
ANTX
$136M
$2.3M 0.4%
474,638
-41,116
-8% -$177K
2026 Q1
1 quarter
PLRX icon
30
Pliant Therapeutics
PLRX
$59.9M
$1.56M 0.27%
1,370,233
-297,367
-18% -$362K
2025 Q1
5 quarters
TECX icon
31
Tectonic Therapeutic
TECX
$417M
$1.37M 0.24%
39,731
-40,141
-50% -$1.18M
2025 Q1
5 quarters
MGTX icon
32
MeiraGTx Holdings
MGTX
$955M
$1.22M 0.21%
90,000
-2,539,971
-97% -$25.2M
2022 Q1
17 quarters
EFOR icon
33
Everforth Inc
EFOR
$1.57B
$1.21M 0.21%
+67,500
New +$1.65M
2026 Q2
0 quarters
RNTX icon
34
Rein Therapeutics
RNTX
$65.1M
$1.14M 0.2%
1,100,000
+688,400
+167% +$833K
2024 Q2
8 quarters
COYA icon
35
Coya Therapeutics
COYA
$105M
$995K 0.17%
170,000
-250,360
-60% -$1.16M
2026 Q1
1 quarter
IMRX icon
36
Immuneering
IMRX
$230M
$184K 0.03%
36,861
-86,548
-70% -$438K
2026 Q1
1 quarter
ACET icon
37
Adicet Bio
ACET
$47.8M
– –
-250,244
Closed -$1.7M –
IMVT icon
38
Immunovant
IMVT
$5.93B
– –
-175,825
Closed -$4.37M –
NVCR icon
39
NovoCure
NVCR
$1.67B
– –
-50,400
Closed -$549K –
OMER icon
40
Omeros
OMER
$1.37B
– –
-174,800
Closed -$1.85M –
PHR icon
41
Phreesia
PHR
$667M
– –
-1,100,000
Closed -$9.22M –
RGNX icon
42
Regenxbio
RGNX
$479M
– –
-200,000
Closed -$1.68M –
ROIV icon
43
Roivant Sciences
ROIV
$24.1B
– –
-180,000
Closed -$4.99M –
SDGR icon
44
Schrodinger
SDGR
$1.94B
– –
-510,578
Closed -$5.8M –
TBI icon
45
Trueblue
TBI
$269M
– –
-249,107
Closed -$974K –
TERN icon
46
DELISTED
Terns Pharmaceuticals
TERN
– –
-202,300
Closed -$10.7M –
TMDX icon
47
Transmedics
TMDX
$2.74B
– –
-5,000
Closed -$497K –
VKTX icon
48
Viking Therapeutics
VKTX
$3.39B
– –
-45,000
Closed -$1.46M –
CON icon
49
Concentra Group Holdings
CON
$4.79B
– –
-505,822
Closed -$10.8M –
UPB icon
50
Upstream Bio Inc
UPB
$194M
– –
-241,123
Closed -$2.17M –
1
2
3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q2 2026 Portfolio in Review

As of Q2 2026, Prosight Management held 51 positions worth $580M, down 4.8% from $610M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Prosight Management's Q2 2026 filing shows 5 new, 16 increased, 15 reduced and 15 closed positions. Its largest new stake was Insmed: 375,609 shares worth $40M. The largest sale was Procept Biorobotics, an estimated $42M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Industrials.

  • Prosight Management's largest Q2 2026 buy was Insmed: 375,609 shares worth $40M.
  • Prosight Management added most to Boston Scientific in Q2 2026, an estimated $25.8M increase.
  • Prosight Management's biggest Q2 2026 reduction was Procept Biorobotics, cutting an estimated $42M.
  • Prosight Management fully exited Concentra Group Holdings in Q2 2026, selling an estimated $10.8M.
  • Prosight Management's ten largest holdings make up 71% of its $580M portfolio in Q2 2026.
  • Prosight Management opened 5 new positions and closed 15 in Q2 2026.
  • Prosight Management's portfolio value fell 4.8% quarter-over-quarter to $580M.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.